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Phosphomannose isomerasee (PMI) deﬁciency or congenital disorders of glycosylation type Ib (CDG Ib) is the
only CDG that can be treated. Despite variable severity leading to dramatically different prognoses, clinical
presentation is relatively homogeneous with liver and digestive features associated with hyperinsulinism
and inconstant thrombosis. A feature of CDG is that coagulation factors are decreased. In our experience,
mannose given orally at least 4 times per day not only transformed lethal CDG Ib into a treatable disease, but
also improved the general condition and digestive symptoms of all reported patients but one. Liver disease,
however, still persisted. Heparin can be used as an alternative to mannose in certain patients, particularly in
the treatment of enteropathy.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Congenital disorders of glycosylation (CDG) result from a defect in
N-glycosylation [1], and phosphomannose isomerase (PMI; E.C
5.3.1.8) deﬁciency is the only CDG (CDG-Ib, OMIM 602579) that can
be treated. This enzyme, located in the cytosol, catalyzes the
isomerisation of fructose 6-phosphate to mannose 6-phosphate
which can also originate from free mannose entering the cell via a
speciﬁc transporter [1] (Fig. 1). Consequently mannose supplementa-
tion is successfully used to treat PMI deﬁciency.
CDG Ib is a rare autosomal recessive disease, with only few
patients (less than 50 cases) reported in comparison with CDG Ia
patients. It should be pointed out, however, that CDG Ib is probably
under-diagnosed.
2. Clinical presentation
The ﬁrst clinical description of CDG-Ib was made by Pedersen in
1980 [2]. Pelletier et al. in 1986 also reported a lethal disease in 4
patients from the “Saguenay-Lac St-Jean” area in Quebec [3]. All
patients died, and diagnosis of CDG Ib was retrospective [4] as the
metabolic error causing CDG Ib was described later [5].ladies métaboliques, Départe-
, rue de Sèvres, F-75015 Paris,
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geneous with liver and digestive feature, associated with mild
hyperinsulinism and inconstant thrombosis [2,3,5–13].
Digestive symptoms are vomiting, intractable diarrhoea and
malnutrition due to protein-losing enteropathy, sometimes associated
with mild villous atrophy [12]. Duodenal biopsies can be normal [7].
The most severe patients, with an onset of their disease in the ﬁrst
months of age, require parenteral nutrition.
Liver disease is revealed by hepatomegaly, sometimes associated
with oedema or anasarca. The liver biopsy reveals a ﬁbrosis very
similar to that of congenital hepatic ﬁbrosis (CHF), with biliary
dystrophy and portal ﬁbrosis [14]. This ﬁbrosis is reported in all
patients but one [8] where liver biopsy was performed [3,5,6,13,15].
Hyperinsulinism is frequently associated with CDG Ib but probably
under diagnosed because hypoglycaemia is moderate or frequently
compensated in patients requiring parenteral nutrition for their
digestive symptoms, including glucose infusion.
Thrombosis is not present in all patients, although frequent. It can
be multiple in the same patient.
Since the ﬁrst report [2], clinical heterogeneity in terms of clinical
presentation and severity of symptoms has been described with
variable prognoses even among siblings. Untreated patients manifest-
ing their disease in the ﬁrst year of age died in the ﬁrst years of life.
Other patients can present with only hepatomegaly and hyperinsulin-
isms, or mild diarrhoea and transaminase cytolysis. Westphal et al.
[13] reported two siblings with the same mutation, with gut and liver
disease. One died at 5 years of agewith hepatic ﬁbrosis while the other
Fig. 1. Biosynthesis of GDP-mannose from the glycolytic intermediate fructose
6-phosphate: phosphomannose isomerase (PMI), phosphomannomutase (PMM)
and GDP-mannose pyrophosphorylase (GMPP). Synthesis of GDP-mannose from
exogenous mannose requires hexokinase (HK) (or glucokinase in the liver) together
with PMM and GMPP.
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no further symptoms following childhood, and no treatment. This
patient currently has a normal life with healthy children.
3. Biological presentation and diagnosis
3.1. Liver cytolysis
Transaminases are usually mildly elevated (among 60 IU/l, normal
values b50; sometimes higher up to 1000 IU/l), while serum bilirubin
and GGT levels are normal.
3.2. Coagulation
As a feature of CDG, factor XI, antithrombin III, proteins C and S are
decreased, down to 5–33%. Prothrombin time is slightly decreased
with a normal factor V level. Like in CDG Ia, thrombosis, more often
than bleeding, can be observed, because of markedly low levels of
several coagulation factors and/or oesophageal varices.
3.3. Liver failure
Hypoalbuminemia (b30 g/l) related to liver dysfunction is present
in severe cases as well as hypocholesterolemia.
3.4. Diagnosis
To ascertain the diagnosis, biochemical and molecular investiga-
tions are necessary, including transferrin western blot and/or iso-
electric focusing of patterns typical of CDG I. PMI deﬁciency is
evidenced in patients' bloodmononuclear cells and/or ﬁbroblasts. The
presence of mutations in theMPI gene evidenced by direct sequencing
conﬁrms the diagnosis.
3.5. Differential diagnosis
Interestingly, contrary to CDG Ia patients, no neurological
symptom has been noted in CDG Ib patients. The lack of psychomotor
retardation, cerebellar hypoplasia, strabismus or lipocutaneous
abnormalities in CDG Ib might limit the diagnosis, as most CDG are
presently associated with these clinical symptoms. Inversely, hyper-insulinism associated with thrombosis, digestive and hepatic failures
can also be present in CDG Ia. Thus, a precise diagnosis with enzymatic
and molecular investigation is required to conﬁrm the diagnosis of
CDG Ib and Ia.
4. Medical treatment by mannose and follow-up
PMI enzyme defect leads to decreased mannose 6-phosphate that
is synthesized from fructose 6-phosphate (Fig. 1). However, mannose
6-phosphate can also originate from free mannose entering the cell
via a speciﬁc transporter [1], demonstrating that mannose supple-
mentation can successfully treat PMI deﬁciency. Presently, CDG Ib is
the only treatable CDG.
Niehues et al. [8] successfully treated a 6 year old CDG Ib patient
using oral mannose with an 11 month follow-up. Clinical response to
mannose was observed within 2 weeks, although a slower improve-
ment in glycosylation of glycoproteins was observed.
Studies have proved that mannose therapy improved the general
condition and digestive symptoms in all reported patients [8,10–
12,15–17] but one [18], whereas the ﬁrst patients with severe clinical
presentations who received no mannose treatment died. Mannose
therapy normalized hypoglycaemia and vomiting after a few weeks,
and the general status of patients dramatically improved. Biological
abnormalities, including diarrhoea, were normalized in the ﬁrst year.
Only hepatomegaly persisted in certain cases.
Oral supplementation of mannose is recommended as it is well
absorbed in the gut. Normal serummannose level in fasting controls is
from 46–65 mM [19]. Blood mannose levels increase in a dose-
dependent fashion with increasing oral doses of mannose. The
clearance half-time of mannose is 4 h [8] and a peak blood mannose
concentration occurs at 1–2 h following ingestion of mannose.
Patients with CDG Ib have less than 10 mM of serum mannose before
treatment [9,15]. Themannose treatment in CDG Ib patients is given in
order to achieve a plasma mannose concentration N20 µmol/l before
mannose administration (T0) and N100 µmol/l 1 h thereafter [19]. The
dose of mannose recommended in CDG Ib patients is 0.2 g/Kg/4 h at
the beginning of the treatment [8]. Following this, patients are treated
with 4 uptakes of mannose. However, the mannose doses depend on
plasma mannose measurement, and the frequency of mannose
uptakes are crucial because of the short clearance half-time mannose.
We recommendmeasuring plasma mannose at T0, at 1 h and 2 h after
mannose uptake. A reduction of the frequency and/or the dose of
mannose administration (for example by increase of the weight of the
patient) can be followed by a recurrence of diarrhoea and a decrease
in the residual mannose level, reversible when mannose treatment is
reintroduced.
Unbound mannose can be determined in blood samples collected
on EDTA in an assay derived from the method of Etchison and Freeze
[20] in specialized laboratories. We proposemeasuring the blood level
of free mannose before and after mannose administration [21].
Oral mannose supplementation is well tolerated, while single
mannose doses of N200 mg/kg body weight can induce osmotic
diarrhoea. No side effects have been reported after 21 days of continue
infusion (5.7 g/kg/day) in CDG I [22], or in the long-term treatment of
CDG Ib patients, followed-up over a 10 year period. To date,
neurological developmentundermannose treatment has beennormal.
Concerning liver disease, Hendriksz et al. [16] observed 3 years of
successful mannose treatment that achieved clinical and biological
improvement, but persistent hepatomegaly. Our experience, as well as
that of other teams, is that while liver disease persists in the most
severe patients, their other symptoms disappear after several months
[15]. Hepatomegaly remains, with some patients having signs of
chronic liver disease, splenomegaly, palmar erythema, persistently
elevated transaminases, symptoms of portal hypertension, and at liver
biopsy proliferating dystrophic and dilated bile ducts, and prominent
portal ﬁbrosis, akin to CHF. Neither inﬂammation, steatosis nor
843P. de Lonlay, N. Seta / Biochimica et Biophysica Acta 1792 (2009) 841–843cholestasis are observed. Thus, mannose does not seem to act
effectively on the liver, even when administered in the ﬁrst months
of life. Liver improvement probably depends on the severity of the
disease at diagnosis, as liver disease seems to evolve by itself.
Abnormal glycosylated proteins in the liver could also interfere with
the normal development of the liver, either by accumulation of an
abnormal product, or more probably by loss of function. Finally, a link
may exist between the progression of liver disease and long-term side
effects of mannose supplementation [23]: Mpi −/− mouse embryos
died around E11.5 under mannose. Mannose supplementation
hastened their death, caused byMan-6-P accumulationwhich inhibits
glucose metabolism (glycolytic enzymes) and depletes intracellular
ATP. Although Pannerselvam et al. [24] showed that incubation with
exogenous mannose transiently corrected altered N-glycosylation in
ﬁbroblasts from patients with CDG I and Alton et al. [19] showed the
feasibility and safety of orally ingested mannose, the toxicity of
mannose remains questionable. Thus, an unsolved issue is the
duration of mannose supplementation, particularly in patients with
mild presentation [13], but also in more severe patients.
There is a possible negative relation between the severity of
hepatic disease and the correction of transferrin proﬁle, due to its
synthesis in the liver. Indeed, CDG Ib patients without any clinical or
biological liver disease [8,16] or few liver symptoms [12] are those
where complete correction of the glycosylation proﬁle is observed
using mannose therapy. All other patients had incomplete normal-
ization of the transferrin isoelectrofocusing proﬁle [15].
Recently, Liem et al. [18] reported an adult patient with CDG Ib
who presented with oedema, diarrhoea, hypoalbuminemia and
pancytopenia and had a history of congenital hepatic ﬁbrosis, portal
hypertension and oesophageal varices. In the past she had had no
positive response to mannose therapy because of associated diar-
rhoea and abdominal pain which increased on mannose supplemen-
tation. Because protein-losing enteropathy was observed, an
alternative therapy was needed. Heparin has been previously used
to treat protein-losing enteropathy, mainly in children using Fontan
procedure [25]. Indeed, mucosal injury and increased lymphatic
pressure as the two mechanisms known to cause protein-losing
enteropathy have been shown to be reversed by heparin sulfate in
several models [26]. Infusion of unfractionated heparin relayed by
subcutaneous injections of unfractionated heparin twice a day was
proposed as a solution, and found to improve the overall clinical
condition. The dosage of heparin was monitored using heparin
antifactor Xa levels, which remained well below the therapeutic
range. Thus, heparin therapy could be an alternative (or be
complementary) to mannose in some patients, particularly in the
case of profuse enteropathy unresponsive to mannose therapy.
Further studies are however necessary to conﬁrm its efﬁcacy on
protein-losing enteropathy and to specify the characteristics of CDG Ib
patients who could require this new therapy.
5. Conclusion
Therapy with mannose has transformed lethal CDG Ib into a
treatable disease, and the success achieved by oral administration of
mannose makes diagnosing PMI deﬁciency all the more important. It
should be pointed out, however, that in some patients this treatment
cannot control post-natal liver disease, possibly a consequence of a
disorder in foetal development. This will probably be a prognostic
factor for the future of such CDG1b patients. Heparin therapy could be
an alternative to mannose to treat protein-losing enteropathy of CDG
Ib patients.
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